Erasca Inc. shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.

The patient, a 66-year-old man, went to the emergency room with severe lung inflammation about a month after starting the company’s therapy. He subsequently died after discontinuing the treatment.